Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GDC-7035 alone and in combination for advanced KRAS G12D-mutant solid tumors
MOH_2025-02-12_013911Phase 2Recruiting
- Sponsor
- Roche
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GDC-7035 in colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Roche. Primary endpoints: Safety, Pharmacokinetics and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
GDC-7035
03
Conditions
colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2025-02-12_013911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-12_013911.